Korea Spent 3.9 Trillion Won on Bio Data, Just 4% on Sharing

South Korea's 3.9 trillion won investment in bio data projects last year reveals a critical imbalance: only 4.2% was spent on data linkage and sharing. This underinvestment directly impedes the ability to connect and utilize health care data across institutions, a fundamental requirement for advanced AI and biotech applications. The report from the National Bio Innovation Committee points out that varying data definitions, units, and coding systems between institutions necessitate extensive refinement before data can be shared, a process that received a mere 0.2% of the total investment. For a nation aiming to be a leader in bio-innovation, this structural issue could significantly slow progress. The focus on generating new data over standardizing and integrating existing datasets limits the practical utility of the overall investment. With 93 of 229 analyzed datasets using project-specific models and none adopting a domestic public standard, the lack of a common data foundation is a major hurdle. The committee's plan to develop policy tasks for data linkage, standardization, and quality control is a necessary step, but the challenge lies in shifting investment priorities to support these foundational elements. Without robust data interoperability, the potential for AI-driven breakthroughs in Korean healthcare and biotechnology will remain constrained.